Disease Overview：Laryngeal Cancer（LC）
Laryngeal cancer is a malignant neoplasm arising from the epithelial cells of the larynx—most commonly squamous cell carcinoma—typically linked to tobacco use, heavy alcohol consumption, and persistent HPV infection. It presents with progressive hoarseness, dysphagia, odynophagia, otalgia, or a palpable neck mass; diagnosis relies on laryngoscopy with biopsy, supplemented by cross-sectional imaging (contrast-enhanced CT or MRI) and PET-CT for staging. Treatment strategy hinges on tumor stage, location (glottic, supraglottic, or subglottic), and patient comorbidities, encompassing transoral laser microsurgery (TLM), open partial laryngectomy, radical radiotherapy (IMRT or proton therapy), or multimodal chemoradiation for advanced disease. Early-stage glottic cancers carry excellent 5-year survival rates (>90%), while locally advanced or nodal disease requires coordinated oncologic care to preserve function and minimize recurrence.
China offers distinct advantages in laryngeal cancer management: its tertiary hospitals house nationally certified head and neck oncology centers staffed by surgeons trained in functional laryngeal preservation techniques and radiation oncologists proficient in adaptive IMRT and image-guided brachytherapy. Advanced platforms—including robotic-assisted TLM systems, PET-MRI hybrid scanners, and AI-integrated treatment planning software—are widely deployed. Clinical outcomes align with international benchmarks: multi-center data from Beijing, Shanghai, and Guangzhou report 3-year locoregional control exceeding 82% for Stage III–IV disease, with voice preservation achieved in over 70% of eligible candidates undergoing organ-sparing protocols. Crucially, comprehensive treatment—including diagnostics, surgery, adjuvant radiotherapy, and rehabilitation—is typically 40–60% more cost-effective than in the US or Western Europe, without compromising evidence-based standards.
As a dedicated medical tourism agency, we facilitate seamless access to these high-caliber services for international patients. We coordinate hospital referrals with top-tier oncology centers, provide itemized, transparent pricing in advance, arrange visa support and accommodation, assign bilingual clinical liaisons, and oversee post-treatment follow-up—all tailored to individual clinical and logistical needs.
Laryngeal Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown for Laryngeal Cancer (Oncology Department)
Non-Surgical / Conservative / Medication Options
*Indicated for early-stage (T1–T2, N0), medically inoperable patients, or as neoadjuvant/adjuvant therapy.*
- •Radiation Therapy (IMRT/VMAT): Primary curative modality for T1–T2 glottic cancer.
- Daily fraction (30 fractions): $4,200–$5,600 (total course) - Weekly blood tests (CBC, liver/kidney function): $45–$65/session × 6 sessions = $270–$390
- •Chemotherapy (Cisplatin-based concurrent CRT): For locally advanced (T3–T4/N+) disease.
- Antiemetics, hydration, electrolyte monitoring: $220–$310/cycle → $660–$930 total
- •Immunotherapy (Pembrolizumab): For recurrent/metastatic PD-L1+ disease (CPS ≥1).
- Baseline PD-L1 IHC testing: $290 - Monthly thyroid/LFT monitoring: $130–$180/month
Surgical / Procedural / Interventional Options
*Eligibility: Resectable disease (T1–T4, N0–N2), adequate pulmonary/cardiac reserve, no distant metastasis.*
- •Transoral Laser Microsurgery (TLM): Gold standard for T1–T2 glottic/supraglottic cancers.
- Procedure (CO₂ laser resection + frozen section): $3,900–$5,100
- •Partial Laryngectomy (Horizontal/Vertical): For T3/T4 with cartilage invasion.
- Surgery + 5-day ICU/stay: $6,800–$8,400
- •Total Laryngectomy + Neck Dissection: For unresectable local disease or salvage after failed RT.
- Surgery + 7-day post-op care + stoma care training: $9,200–$11,600
Special / Complex Condition Options
- •Recurrent/Residual Disease Post-RT: Salvage TLM or total laryngectomy — add $1,100–$1,500 for repeat imaging and functional assessment.
- •Nodal Metastasis (N2c/N3): Modified radical neck dissection + adjuvant CRT — adds $2,400–$3,100 to base surgical cost.
- •Tracheoesophageal Puncture (TEP) + Voice Prosthesis: For voice rehabilitation post-total laryngectomy — $1,350–$1,780 (procedure + prosthesis + speech therapy x4 sessions).
Quick Selection Guide
- •<65 years, T1–T2, no comorbidities: TLM ($3,900–$5,100) — optimal functional preservation, lowest recurrence risk.
- •≥75 years or severe COPD/CHF: Definitive IMRT ($4,200–$5,600) — avoids anesthesia risk; includes supportive lab monitoring.
- •T3–T4 with cartilage involvement: Partial laryngectomy ($6,800–$8,400) — superior oncologic control vs. RT alone.
- •Budget-constrained (≤$5,000): Concurrent CRT ($4,000–$5,300) — balances efficacy and affordability for locally advanced disease.
- •PD-L1+ recurrent/metastatic: Pembrolizumab monotherapy ($1,850–$2,200/dose) — first-line if platinum-ineligible; requires confirmatory IHC ($290).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Laryngeal Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Laryngeal Cancer treatment with China top medical destinations:
